Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Prevalence and predictors of probable depression in prostate cancer survivors.

Erim DO, Bensen JT, Mohler JL, Fontham ETH, Song L, Farnan L, Delacroix SE, Peters ES, Erim TN, Chen RC, Gaynes BN.

Cancer. 2019 Oct 1;125(19):3418-3427. doi: 10.1002/cncr.32338. Epub 2019 Jun 27.

PMID:
31246284
2.

NCCN Guidelines Updates: Management of Prostate Cancer.

Mohler JL, Antonarakis ES.

J Natl Compr Canc Netw. 2019 May 1;17(5.5):583-586. doi: 10.6004/jnccn.2019.5011.

PMID:
31117038
3.

Patterns and predictors of self-reported clinical diagnosis and treatment for depression in prostate cancer survivors.

Erim DO, Bensen JT, Mohler JL, Fontham ETH, Song L, Farnan L, Delacroix SE, Peters ES, Erim TN, Chen RC, Gaynes BN.

Cancer Med. 2019 Jul;8(8):3648-3658. doi: 10.1002/cam4.2239. Epub 2019 May 20.

4.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
5.

Association among plasma 1,25(OH)2 D, ratio of 1,25(OH)2 D to 25(OH)D, and prostate cancer aggressiveness.

Ramakrishnan S, Steck SE, Arab L, Zhang H, Bensen JT, Fontham ETH, Johnson CS, Mohler JL, Smith GJ, Su LJ, Woloszynska A.

Prostate. 2019 Jul;79(10):1117-1124. doi: 10.1002/pros.23824. Epub 2019 May 11.

6.

Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer.

Fiandalo MV, Gewirth DT, Mohler JL.

Asian J Urol. 2019 Jan;6(1):50-56. doi: 10.1016/j.ajur.2018.09.002. Epub 2018 Sep 26. Review.

7.

In honor of Dr. Donald S. Coffey - Prostate cancer biology and therapy.

Gao AC, Mohler JL.

Asian J Urol. 2019 Jan;6(1):1-2. doi: 10.1016/j.ajur.2018.10.002. Epub 2018 Nov 3. No abstract available.

8.

Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.

Kumar R, Bhat TA, Walsh EM, Chaudhary AK, O'Malley J, Rhim JS, Wang J, Morrison CD, Attwood K, Bshara W, Mohler JL, Yadav N, Chandra D.

Cancer Res. 2019 Apr 1;79(7):1353-1368. doi: 10.1158/0008-5472.CAN-18-2383. Epub 2019 Feb 14.

PMID:
30765600
9.

Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

Venkadakrishnan VB, DePriest AD, Kumari S, Senapati D, Ben-Salem S, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, Shah RB, Jamieson C, Dehm SM, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers HV.

Oncogene. 2019 Jun;38(23):4496-4511. doi: 10.1038/s41388-019-0732-7. Epub 2019 Feb 11.

PMID:
30742064
10.

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC, du Plessis M, Davicioni E, Fleshner N, Lane BR, Ross AE, Davis JW, Mohler JL, Trock BJ, Klein EA, Tosoian JJ, Hyndman ME, Bismar TA.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):399-405. doi: 10.1038/s41391-018-0101-6. Epub 2018 Dec 12.

PMID:
30542054
11.

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series.

Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ.

Prostate Cancer Prostatic Dis. 2019 May;22(2):309-316. doi: 10.1038/s41391-018-0106-1. Epub 2018 Nov 1.

12.

Dietary patterns based on the Mediterranean diet and DASH diet are inversely associated with high aggressive prostate cancer in PCaP.

Schneider L, Su LJ, Arab L, Bensen JT, Farnan L, Fontham ETH, Song L, Hussey J, Merchant AT, Mohler JL, Steck SE.

Ann Epidemiol. 2019 Jan;29:16-22.e1. doi: 10.1016/j.annepidem.2018.08.012. Epub 2018 Sep 5.

PMID:
30268488
13.

The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.

Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ETH, Farnan L, Drake BF, Olshan AF, Bensen JT.

Cancer Causes Control. 2018 Nov;29(11):1143-1150. doi: 10.1007/s10552-018-1087-z. Epub 2018 Sep 28.

PMID:
30267174
14.

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.

Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, Mohler JL, Wang J, Zhao R, Kirk J, Chen X, Tang DG.

Nat Commun. 2018 Sep 6;9(1):3600. doi: 10.1038/s41467-018-06067-7.

15.

Proteomic Analysis of Charcoal-Stripped Fetal Bovine Serum Reveals Changes in the Insulin-like Growth Factor Signaling Pathway.

Tu C, Fiandalo MV, Pop E, Stocking JJ, Azabdaftari G, Li J, Wei H, Ma D, Qu J, Mohler JL, Tang L, Wu Y.

J Proteome Res. 2018 Sep 7;17(9):2963-2977. doi: 10.1021/acs.jproteome.8b00135. Epub 2018 Aug 3.

PMID:
30014700
16.

Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects.

Cook SF, Fiandalo MV, Watt DS, Wu Y, Mohler JL, Bies RR.

Prostate. 2018 Jun 25. doi: 10.1002/pros.23665. [Epub ahead of print]

PMID:
29938815
17.

Modelling attrition and nonparticipation in a longitudinal study of prostate cancer.

Spiers S, Oral E, Fontham ETH, Peters ES, Mohler JL, Bensen JT, Brennan CS.

BMC Med Res Methodol. 2018 Jun 20;18(1):60. doi: 10.1186/s12874-018-0518-6.

18.

NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.

Carroll PH, Mohler JL.

J Natl Compr Canc Netw. 2018 May;16(5S):620-623. doi: 10.6004/jnccn.2018.0036.

PMID:
29784740
19.

Calcium, magnesium, and whole-milk intakes and high-aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP).

Steck SE, Omofuma OO, Su LJ, Maise AA, Woloszynska-Read A, Johnson CS, Zhang H, Bensen JT, Fontham ETH, Mohler JL, Arab L.

Am J Clin Nutr. 2018 May 1;107(5):799-807. doi: 10.1093/ajcn/nqy037.

PMID:
29722851
20.

Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC.

Allott EH, Farnan L, Steck SE, Song L, Arab L, Su LJ, Fontham ETH, Mohler JL, Bensen JT.

Prostate. 2018 Aug;78(11):857-864. doi: 10.1002/pros.23644. Epub 2018 May 1.

PMID:
29717502
21.

A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer.

Mohler JL.

Am J Clin Exp Urol. 2018 Apr 1;6(2):101-106. eCollection 2018. Review.

22.

Development of a Patient-Based Model for Estimating Operative Times for Robot-Assisted Radical Prostatectomy.

Huben NB, Hussein AA, May PR, Whittum M, Krasowski C, Ahmed YE, Jing Z, Khan H, Kim HL, Schwaab T, Underwood W, Kauffman EC, Mohler JL, Guru KA.

J Endourol. 2018 Aug;32(8):730-736. doi: 10.1089/end.2018.0249.

23.

Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade.

Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Mantione KM, Li Y, Attwood KM, Azabdaftari G, Wu Y, Watt DS, Wilson EM, Mohler JL.

Oncotarget. 2018 Jan 10;9(13):11227-11242. doi: 10.18632/oncotarget.24107. eCollection 2018 Feb 16.

24.

Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.

Fiandalo MV, Wilton JH, Mantione KM, Wrzosek C, Attwood KM, Wu Y, Mohler JL.

Prostate. 2018 Feb;78(3):213-221. doi: 10.1002/pros.23459. Epub 2017 Dec 1.

25.

Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.

Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM Jr, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA; PRACTICAL/ELLIPSE Consortium.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx084.

26.

Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4).

Frasinyuk MS, Zhang W, Wyrebek P, Yu T, Xu X, Sviripa VM, Bondarenko SP, Xie Y, Ngo HX, Morris AJ, Mohler JL, Fiandalo MV, Watt DS, Liu C.

Org Biomol Chem. 2017 Sep 20;15(36):7623-7629. doi: 10.1039/c7ob01584d.

27.

Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.

Nunez Bragayrac LA, Murekeyisoni C, Vacchio MJ, Attwood K, Mehedint DC, Mohler JL, Azabdaftari G, Xu B, Kauffman EC.

Prostate. 2017 Jul;77(10):1076-1081. doi: 10.1002/pros.23364. Epub 2017 May 26.

PMID:
28547760
28.

Lipid degradation promotes prostate cancer cell survival.

Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG.

Oncotarget. 2017 Jun 13;8(24):38264-38275. doi: 10.18632/oncotarget.16123.

29.

The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC.

Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ETH, Hendrix LH, Farnan L, Olshan AF, Bensen JT.

Prostate. 2017 Jun;77(8):878-887. doi: 10.1002/pros.23342. Epub 2017 Mar 6.

30.

Unit Nonresponse in a Population-Based Study of Prostate Cancer.

Oral E, Simonsen N, Brennan C, Berken J, Su LJ, Mohler JL, Bensen JT, Fontham ET.

PLoS One. 2016 Dec 16;11(12):e0168364. doi: 10.1371/journal.pone.0168364. eCollection 2016.

31.

Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation: intraoperative assessment of lymph node dissection after robot-assisted radical cystectomy for bladder cancer.

Hussein AA, Hinata N, Dibaj S, May PR, Kozlowski JD, Abol-Enein H, Abaza R, Eun D, Khan MS, Mohler JL, Agarwal P, Pohar K, Sarle R, Boris R, Mane SS, Hutson A, Guru KA.

BJU Int. 2017 Jun;119(6):879-884. doi: 10.1111/bju.13748. Epub 2017 Jan 18.

32.

Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer.

Su S, Parris AB, Grossman G, Mohler JL, Wang Z, Wilson EM.

Prostate. 2017 Apr;77(5):505-516. doi: 10.1002/pros.23288. Epub 2016 Dec 14.

PMID:
27976415
33.

A four gene signature predictive of recurrent prostate cancer.

Komisarof J, McCall M, Newman L, Bshara W, Mohler JL, Morrison C, Land H.

Oncotarget. 2017 Jan 10;8(2):3430-3440. doi: 10.18632/oncotarget.13837.

34.

Development and Validation of an Objective Scoring Tool for Robot-Assisted Radical Prostatectomy: Prostatectomy Assessment and Competency Evaluation.

Hussein AA, Ghani KR, Peabody J, Sarle R, Abaza R, Eun D, Hu J, Fumo M, Lane B, Montgomery JS, Hinata N, Rooney D, Comstock B, Chan HK, Mane SS, Mohler JL, Wilding G, Miller D, Guru KA; Michigan Urological Surgery Improvement Collaborative and Applied Technology Laboratory for Advanced Surgery Program.

J Urol. 2017 May;197(5):1237-1244. doi: 10.1016/j.juro.2016.11.100. Epub 2016 Nov 29.

PMID:
27913152
35.

The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.

Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ET, Hendrix LH, Farnan L, Olshan AF, Bensen JT.

Cancer Causes Control. 2016 Dec;27(12):1475-1485. Epub 2016 Nov 9.

36.

Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy.

Ondracek RP, Kattan MW, Murekeyisoni C, Yu C, Kauffman EC, Marshall JR, Mohler JL.

J Natl Compr Canc Netw. 2016 Nov;14(11):1395-1401.

37.

Quality of care received and patient-reported regret in prostate cancer: Analysis of a population-based prospective cohort.

Holmes JA, Bensen JT, Mohler JL, Song L, Mishel MH, Chen RC.

Cancer. 2017 Jan 1;123(1):138-143. doi: 10.1002/cncr.30315. Epub 2016 Sep 13.

38.

Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project.

Allott EH, Arab L, Su LJ, Farnan L, Fontham ET, Mohler JL, Bensen JT, Steck SE.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):48-54. doi: 10.1038/pcan.2016.39. Epub 2016 Sep 6.

PMID:
27595916
39.

Characterization of Prostate Cancer in a Functional Eunuch.

Stocking JJ, Fiandalo MV, Pop EA, Wilton JH, Azabdaftari G, Mohler JL.

J Natl Compr Canc Netw. 2016 Sep;14(9):1054-60.

40.

Development and Validation of a Quality Assurance Score for Robot-assisted Radical Cystectomy: A 10-year Analysis.

Hussein AA, Dibaj S, Hinata N, Field E, O'leary K, Kuvshinoff B, Mohler JL, Wilding G, Guru KA.

Urology. 2016 Nov;97:124-129. doi: 10.1016/j.urology.2016.06.063. Epub 2016 Aug 1.

PMID:
27491964
41.

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.

Shourideh M, Azabdaftari G, Attwood K, DePriest A, Wadosky KM, Gillard BM, Karasik E, Heemers H, Kyprianou N, Gelman IH, Corey E, Vessella RL, Mohler JL, Koochekpour S.

Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016. doi: 10.1158/1078-0432.CCR-16-0137. [Epub ahead of print] Retraction in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3973.

PMID:
27458247
42.

Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.

Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, Gomez EC, Murakam M, Glenn ST, Conroy J, Morrison C, Azabdaftari G, Mohler JL, Liu S, Heemers HV.

Eur Urol. 2017 Feb;71(2):183-192. doi: 10.1016/j.eururo.2016.07.008. Epub 2016 Jul 21.

43.

Androgen Deprivation Therapy for Advanced Prostate Cancer: Can Evolution Be Accelerated?

Mohler JL.

J Natl Compr Canc Netw. 2016 Jun;14(6):701-3. No abstract available.

PMID:
27283162
44.

Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.

Shourideh M, DePriest A, Mohler JL, Wilson EM, Koochekpour S.

Prostate. 2016 Sep;76(12):1067-77. doi: 10.1002/pros.23190. Epub 2016 Jun 8.

PMID:
27271795
45.

Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP).

Antwi SO, Steck SE, Su LJ, Hebert JR, Zhang H, Craft NE, Fontham ET, Smith GJ, Bensen JT, Mohler JL, Arab L.

Prostate. 2016 Sep;76(12):1053-66. doi: 10.1002/pros.23189. Epub 2016 Jun 8.

46.

Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management.

Mohler JL.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):663-5.

PMID:
27226508
47.

Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance.

Al-Tartir T, Murekeyisoni C, Attwood K, Badkhshan S, Mehedint D, Safwat M, Guru K, Mohler JL, Kauffman EC.

J Urol. 2016 Oct;196(4):1061-8. doi: 10.1016/j.juro.2016.05.003. Epub 2016 May 6.

PMID:
27157375
48.

Antineoplastic Isoflavonoids Derived from Intermediate ortho-Quinone Methides Generated from Mannich Bases.

Frasinyuk MS, Mrug GP, Bondarenko SP, Khilya VP, Sviripa VM, Syrotchuk OA, Zhang W, Cai X, Fiandalo MV, Mohler JL, Liu C, Watt DS.

ChemMedChem. 2016 Mar 17;11(6):600-11. doi: 10.1002/cmdc.201600008. Epub 2016 Feb 17.

49.

Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.

Doshi C, Vacchio M, Attwood K, Murekeyisoni C, Mehedint DC, Badkhshan S, Azabdaftari G, Sule N, Guru KA, Mohler JL, Kauffman EC.

Prostate. 2016 Jun;76(8):715-21. doi: 10.1002/pros.23166. Epub 2016 Feb 16.

50.

Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action.

DePriest AD, Fiandalo MV, Schlanger S, Heemers F, Mohler JL, Liu S, Heemers HV.

Database (Oxford). 2016 Feb 13;2016. pii: bav125. doi: 10.1093/database/bav125. Print 2016.

Supplemental Content

Loading ...
Support Center